Knowthestock.com
ATHX - Athersys Inc
Compare

Sell

Weak Growth●Earnings/Profit is Negative

24%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 1141.38%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -5469.79%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 2.38
Debt Ratio is 0.39
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Athersys Inc (ATHX) - http://www.athersys.com/
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived 'off-the-shelf' stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.
Exchange - NASDAQ CAPITAL MARKET
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Gil Van Bokkelen
    Close
Cookie Policy
Disclaimer
Privacy Policy
Terms of Service
About Us
Contact Us
Help
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.